RANI THERAPEUTICS HOLDINGS-A (RANI)
US7530181004 - Common Stock
These stocks are gapping in today's session
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023
RANI stock results show that Rani Therapeutics Hldgs beat analyst estimates for earnings per share the fourth quarter of 2023.
RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rani Therapeutics Hldgs (NASDAQ:RANI) just reported results for the fourth quar...
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical...
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) on behalf of the company's...
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study – - Preclinical data...
Rani Therapeutics CEO discloses purchase of 10K shares (NASDAQ:RANI)
Rani Therapeutics CEO purchases 10,000 shares worth $22,700, increasing ownership to 484,455 shares. 5 insider trades in the past 3 months.
Rani Therapeutics CEO Talat Imran purchases 5,000 shares (NASDAQ:RANI)
RANI's CEO, Talat Imran, acquires 5,000 shares in the company, totaling $12,850. Four insider trades occurred in the last three months.
Rani Therapeutics says CEO Imran buys 20K class A shares (NASDAQ:RANI)
RANI CEO Talat Imran purchased 20K class A shares at $2.05, contributing to the company's overall net insider buying activity of 56K shares.
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - ...
Canaccord believes Rani restructuring will help speed development (RANI)
Canaccord Genuity believes Rani Therapeutics' (RANI) restructuring plan will help speed up the pace of the company's lead drug development programs. Read more here.
Rani to cut 25% of workforce as it reprioritizes drug programs (RANI)
Rani Therapeutics (RANI) plans to cut around 25% of its workforce as it prioritizes three drug programs and expands its manufacturing footprint. Read more here.
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
- RaniPill® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) - - RaniPill® HC has achieved a cumulative >90%...
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results...
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success...
Rani Therapeutics to Participate in September Investor Conferences
SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...